Opium use: An emerging risk factor for cancer?

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages

  Kamangar, Farin ^a,b   Shakeri, Ramin ^b   Malekzadeh, Reza ^b   Islami, Farhad ^b,c  

^a MORGAN STATE UNIVERSITY   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; OPIATE;

BLADDER CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; ESOPHAGUS CANCER; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; LARYNX CANCER; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; NONHUMAN; OBSERVATIONAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SMOKING; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA;

HUMANS; INCIDENCE; NEOPLASMS; ODDS RATIO; OPIOID-RELATED DISORDERS; OPIUM; RISK ASSESSMENT; RISK FACTORS;

EID: 84892973432     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70550-3     Document Type: Review

References (55)

1. Aggrawal A Narcotic drugs 1995, National Book Trust, New Delhi.
2. World Drug Report 2013 2013, United Nations Office of Drugs and Crime (UNODC), United Nations Publication, Geneva.
3. The opium/heroin market United Nations Office of Drugs and Crime (UNODC), (accessed Oct 20, 2013). http://www.unodc.org/documents/data-and-analysis/WDR2011/The_opium-heroin_market.pdf.
4. Heydari M, Hashempur MH, Zargaran A Medicinal aspects of opium as described in Avicenna's Canon of Medicine. Acta Med Hist Adriat 2013, 11:101-112.
5. Golden RL William Osler, urolithiasis, and God's own medicine. Urology 2009, 74:517-521.
6. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1564-1574.
7. Shakeri R, Kamangar F, Nasrollahzadeh D, et al. Is opium a real risk factor for esophageal cancer or just a methodological artifact? Hospital and neighborhood controls in case-control studies. PLoS One 2012, 7:e32711.
8. Shakeri R, Malekzadeh R, Etemadi A, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer 2013, 133:455-461.
9. Khoo R Radiotherapy of carcinoma of the larynx. Ann Acad Med Singapore 1981, 10:307-310.
10. Mousavi MR, Damghani MA, Haghdoust AA, Khamesipour A Opium and risk of laryngeal cancer. Laryngoscope 2003, 113:1939-1943.
11. MacLennan R, Da CJ, Day NE, Law CH, Ng YK, Shanmugaratnam K Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. Int J Cancer 1977, 20:854-860.
12. Behmard S, Sadeghi A, Mohareri MR, Kadivar R Positive association of opium addiction and cancer of the bladder. Results of urine cytology in 3,500 opium addicts. Acta Cytol 1981, 25:142-146.
13. Ketabchi A, Gharaei M, Ahmadinejad M, Meershekari T Evaluation of bladder cancer in opium addicted patients in the Kerman Province, Iran, from 1999 to 2003. J Res Med Sci 2005, 10:355-357.
14. Nourbakhsh A, Mohseni MG, Hatmi ZN Opium use in transitional cell carcinoma of the urinary bladder. Acta Med Iran 2006, 44:263-267.
15. Shakhssalim N, Hosseini SY, Basiri A, Eshrati B, Mazaheri M, Soleimanirahbar A Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev 2010, 11:601-606.
16. Hosseini SY, Safarinejad MR, Amini E, Hooshyar H Opium consumption and risk of bladder cancer: a case-control analysis. Urol Oncol 2010, 28:610-616.
17. Ghadirian P, Stein GF, Gorodetzky C, et al. Oesophageal cancer studies in the Caspian littoral of Iran: some residual results, including opium use as a risk factor. Int J Cancer 1985, 35:593-597.
18. Malekzadeh MM, Khademi H, Pourshams A, et al. Opium use and risk of mortality from digestive diseases: a prospective cohort study. Am J Gastroenterol 2013, 108:1757-1765.
19. Sadjadi A, Derakhshan MH, Yazdanbod A, et al. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions. Int J Cancer 2014, 134:181-188.
20. Naghibzadeh Taham A, Khanjani N, Yazdi Feizabadi Y, Varzandeh M, Haghdoost AA. Opium use as a risk factor for upper gastro-intestinal cancers, a population based case-control study in Iran. Arch Iran Med (in press).
21. Sadeghi A, Behmard S, Vesselinovitch SD Opium: a potential urinary bladder carcinogen in man. Cancer 1979, 43:2315-2321.
22. Aliasgari MA, Kaviani A, Gachkar L, Hosseini-Nassab SR Is bladder cancer more common among opium addicts?. Urol J 2004, 1:253-255.
23. Islami F, Kamangar F, Aghcheli K, et al. Epidemiologic features of upper gastrointestinal tract cancer in northeastern Iran. Br J Cancer 2004, 90:1402-1406.
24. Kamangar F, Malekzadeh R, Dawsey SM, Saidi F Esophageal cancer in Northeastern Iran: a review. Arch Iran Med 2007, 10:70-82.
25. Sadjadi A, Yazdanbod A, Lee YY, et al. Serum ghrelin; a new surrogate marker of gastric mucosal alterations in upper gastrointestinal carcinogenesis. PLoS One 2013, 8:e74440.
26. Salehi A, Khezri AA, Malekmakan L, Aminsharifi A Epidemiologic status of bladder cancer in Shiraz, southern Iran. Asian Pac J Cancer Prev 2011, 12:1323-1327.
27. Yavari P, Sadrolhefazi B, Mohagheghi MA, Mehrazin R A descriptive retrospective study of bladder cancer at a hospital in Iran (1973-2003). Asian Pac J Cancer Prev 2009, 10:681-684.
28. Masjedi MR, Naghan PA, Taslimi S, et al. Opium could be considered an independent risk factor for lung cancer: a case-control study. Respiration 2013, 85:112-118.
29. Khademi H, Malekzadeh R, Pourshams A, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50000 adults in Iran. BMJ 2012, 344:e2502.
30. Nasrollahzadeh D, Kamangar F, Aghcheli K, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer 2008, 98:1857-1863.
31. Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer 1973, 28:197-214.
32. Esophageal cancer studies in the Caspian littoral of Iran: results of population studies-a prodrome. J Natl Cancer Inst 1977, 59:1127-1138. Joint Iran-IARC Study Group.
33. Sadeghi A, Behmard S Cancer of the bladder in Southern Iran. Cancer 1978, 42:353-356.
34. Pourshams A, Khademi H, Malekshah AF, et al. Cohort profile: the Golestan Cohort Study-a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol 2010, 39:52-59.
35. Kamangar F, Chow WH, Abnet C, Dawsey M Environmental causes of esophageal cancer. Gastroenterol Clin North Am 2009, 38:27-57.
36. Abnet CC, Freedman ND, Hu N, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 2010, 42:764-767.
37. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010, 42:978-984.
38. Brennan P, Hainaut P, Boffetta P Genetics of lung-cancer susceptibility. Lancet Oncol 2011, 12:399-408.
39. Wu C, Kraft P, Zhai K, et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet 2012, 44:1090-1097.
40. Shi Y, Hu Z, Wu C, et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet 2011, 43:1215-1218.
41. Hewer T, Rose E, Ghadirian P, et al. Ingested mutagens from opium and tobacco pyrolysis products and cancer of the oesophagus. Lancet 1978, 312:494-496.
42. Malaveille C, Friesen M, Camus AM, et al. Mutagens produced by the pyrolysis of opium and its alkaloids as possible risk factors in cancer of the bladder and oesophagus. Carcinogenesis 1982, 3:577-585.
43. Perry PE, Thomson EJ, Vijayalaxmi, Evans HJ, Day NE, Bartsch H Induction of SCE by opium pyrolysates in CHO cells and human peripheral blood lymphocytes. Carcinogenesis 1983, 4:227-230.
44. Friesen M, O'Neill IK, Malaveille C, et al. Characterization and identification of 6 mutagens in opium pyrolysates implicated in oesophageal cancer in Iran. Mutat Res 1985, 150:177-191.
45. Dowlatshahi K, Miller RJ Role of opium in esophageal cancer: a hypothesis. Cancer Res 1985, 45:1906-1907.
46. Kalant H Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. Addiction 1997, 92:267-277.
47. Auge C, Chene G, Dubourdeau M, et al. Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder. Eur J Pharmacol 2013, 707:32-40.
48. Franzel RE, Hargis KJ, Casas AW Synergism between morphine and cyclophosphamide causes fatal urinary bladder cystitis. Fed Proc 1977, 36:1001.
49. Kharabaf S, Abdollahi M Science growth in Iran over the past 35 years. J Res Med Sci 2012, 17:275-279.
50. Dhalla IA, Persaud N, Juurlink DN Facing up to the prescription opioid crisis. BMJ 2011, 343:d5142.
51. Dowell D, Kunins HV, Farley TA Opioid analgesics-risky drugs, not risky patients. JAMA 2013, 309:2219-2220.
52. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010, 170:1968-1976.
53. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011, 5:e13-e22.
54. Randall D, Degenhardt L, Vajdic CM, et al. Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. Aust N Z J Public Health 2011, 35:220-225.
55. Abnet CC, Saadatian-Elahi M, Pourshams A, et al. Reliability and validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev 2004, 13:1068-1070.